iNKT cells: an emerging promise for immunotherapy

Keywords

Invariant natural killer T cells / Immunotherapy / Adoptive cellular therapy / SARS-CoV-2 / Cancer

Ethical statements

Not applicable.

Author contributions

The authors confirm contributions to the paper as follows: visualization, software, funding acquisition, draft manuscript preparation: Wang X; writing - review & editing: Wang X, Jin J; resources, project administration: Zhang L. All authors reviewed the results and approved the final version of the manuscript.

Data availability

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (Grant No. 82073948).

Conflict of interest

The authors declare that they have no conflict of interest.

References

[1] Godfrey DI, Kronenberg M. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. The Journal of Clinical Investigation 114:1379-1388

[2] Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, et al. 2011. Invariant natu-ral killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nature Immunology 12:966-974

[3] Berzins SP, Smyth MJ, Baxter AG. 2011. Presumed guilty: natural killer T cell defects and human disease. Nature Reviews Immunology 11:131-142

[4] Courtney AN, Tian G, Metelitsa LS. 2023. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood 141:869-876

[5] Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, et al. 2024. A phase 1/ 2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nature Commu-nications 15:974

[6] Garmezy B, Grossman JE, Buell J, Favano T, Stebbing J, et al. 2025. Salvage therapy with allogeneic invariant natural killer cells in a heav-ily pre-treated germ cell tumor. Oncogene 44:2792-2795

[7] Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS, et al. 2024. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). Onco-gene 43:758-762

[8] van der Vliet HJJ, et al.von Blomberg BME, Hazenberg MD, Nishi N, Otto SA, 2002. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. The Journal of Immunology 168:1490-1495

[9] Juno JA, Keynan Y, Fowke KR. 2012. Invariant NKT cells: regulation and function during viral infection. PLoS Pathogens 8:e1002838

[10] Rajashekar V, Stern L, Almeida CF, Slobedman B, Abendroth A. 2024. The surveillance of viral infections by the unconventional Type I NKT cell. Frontiers in Immunology 15:1472854

[11] Lu H, Liu Z, Deng X, Chen S, Zhou R, et al. 2023. Potent NKT cell ligands overcome SARS-CoV-2 immune evasion to mitigate viral pathogenesis in mouse models. PLoS Pathogens 19:e1011240

[12] Paul S, Chhatar S, Mishra A, Lal G. 2019. Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor. Journal for Immunotherapy of Cancer 7:208

[13] Salio M, Silk JD, Jones EY, Cerundolo V. 2014. Biology of CD1- and MR1-restricted T cells. Annual Review of Immunology 32:323-366

[14] Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, et al. 2018. Bimodal CD40/fas-dependent crosstalk between iNKT cells and tumor-asso-ciated macrophages impairs prostate cancer progression. Cell Reports 22:3006-3020

[15] Li YR, Zhu Y, Halladay T, Yang L. 2025. In vivo CAR engineering for immunotherapy. Nature Reviews Immunology 25:725-744

[16] Han X, Liao R, Li X, Zhang C, Huo S, et al. 2025. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy 10:262

[17] Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, et al. 2024. CAR-redi-rected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nature Cancer 5:1607-1621

[18] Berrien-Elliott MM, Jacobs MT, Fehniger TA. 2023. Allogeneic natural killer cell therapy. Blood 141:856-868

[19] Myers JA, Miller JS. 2021. Exploring the NK cell platform for cancer immunotherapy. Nature Reviews Clinical Oncology 18:85-100